Get ahead in your career - track and evidence all your medical learning

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate | Key-points-from-the-evidence | Advice | NICE

Limited evidence from 1 RCT suggests that lisdexamfetamine dimesylate produces clinically meaningful benefits in ADHD symptoms compared with placebo. The adverse effect profile appears similar to other stimulant drugs, although theoretical advantages in terms of improved adherence and reduced abu...
Shared By Jeremy Walker on Wednesday 12th August 2015